MustGrow Biologics Corp. Stock Canadian Securities Exchange
Equities
MGRO
CA62822A1030
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- CAD | -.--% | +6.74% | -28.57% |
Apr. 23 | MustGrow Biologics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 22 | MustGrow Biologics Corp.(TSXV:MGRO) dropped from S&P/TSX Venture Composite Index | CI |
Sales 2022 | 6.48K 4.73K | Sales 2023 | 4.71M 3.44M | Capitalization | 66.39M 48.51M |
---|---|---|---|---|---|
Net income 2022 | -5M -3.65M | Net income 2023 | - 0 | EV / Sales 2022 | 26,167 x |
Net cash position 2022 | 6.26M 4.57M | Net cash position 2023 | 6.06M 4.43M | EV / Sales 2023 | 12.8 x |
P/E ratio 2022 |
-31.2
x | P/E ratio 2023 |
-95.1
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 86.21% |
Managers | Title | Age | Since |
---|---|---|---|
Corey Giasson
CEO | Chief Executive Officer | 46 | 18-03-14 |
Todd Lahti
DFI | Director of Finance/CFO | 58 | 18-12-16 |
Colin Bletsky
COO | Chief Operating Officer | 49 | 18-03-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Brian Quigley
BRD | Director/Board Member | 50 | 19-07-16 |
Brad Munro
CHM | Chairman | 64 | 18-03-14 |
Corey Giasson
CEO | Chief Executive Officer | 46 | 18-03-14 |
1st Jan change | Capi. | |
---|---|---|
+4.09% | 43.84B | |
+47.81% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- MGRO Stock
- MGRO Stock